Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 367

1.

Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.

Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y.

BJU Int. 2012 Oct;110(7):967-72. doi: 10.1111/j.1464-410X.2012.11060.x.

2.
3.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

4.

[Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].

Descazeaud A, Mignard JP, Davin JL, Irani J.

Prog Urol. 2009 Oct;19(9):624-31. doi: 10.1016/j.purol.2009.06.009. French.

PMID:
19800553
5.

Intravesical gemcitabine for non-muscle invasive bladder cancer.

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. Review.

PMID:
22259002
6.

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.

Joudi FN, Smith BJ, O'Donnell MA, Konety BR.

Urology. 2003 Dec;62(6):1083-8.

PMID:
14665360
7.

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.

Gandhi NM, Morales A, Lamm DL.

BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Review.

9.

[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].

Rouprêt M, Neuzillet Y, Larré S, Pignot G, Coloby P, Rébillard X, Mongiat-Artus P, Chartier-Kastler E, Soulié M, Pfister C; Comité de cancérologie de l'Association française d'urologie..

Prog Urol. 2012 Nov;22(15):920-31. doi: 10.1016/j.purol.2012.05.002. French.

PMID:
23102014
10.

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology..

Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Review.

PMID:
23827737
11.
12.

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.

Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038.

PMID:
19409692
13.
14.

Intravesical therapy for bladder cancer.

Williams SK, Hoenig DM, Ghavamian R, Soloway M.

Expert Opin Pharmacother. 2010 Apr;11(6):947-58. doi: 10.1517/14656561003657145. Review.

PMID:
20205607
15.

Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.

Rao MV, Ellimoottil C, Sondej T, Flanigan RC, Quek ML.

Urol Oncol. 2013 Aug;31(6):857-61. doi: 10.1016/j.urolonc.2011.07.005.

PMID:
21868262
16.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Review.

PMID:
23628309
17.

[Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].

Steinbach F, Schuster F.

Aktuelle Urol. 2005 Aug;36(4):337-41. German.

PMID:
16110407
18.

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA.

Urology. 2008 Feb;71(2):297-301. doi: 10.1016/j.urology.2007.09.050.

PMID:
18308107
20.

Supplemental Content

Support Center